The real problem is the whole model is based on patent drugs.
Patent drugs have a limited profit lifetime, but completely unknown risks due to their novelty.
Now if some of these companies were really smart, hint, hint, they would go for really effective combination nutrients (read: very advanced dietary supplements) that do things that nobody else does.
This is the business model known as "we are not the best at what we do, but we are the only ones that do it" which creates a lot of copycats, and sadly Lilly has become a copycat itself
The real problem is the whole model is based on patent drugs.
Patent drugs have a limited profit lifetime, but completely unknown risks due to their novelty.
Now if some of these companies were really smart, hint, hint, they would go for really effective combination nutrients (read: very advanced dietary supplements) that do things that nobody else does.
This is the business model known as "we are not the best at what we do, but we are the only ones that do it" which creates a lot of copycats, and sadly Lilly has become a copycat itself
I agree that the model based compltely on patented drugs is flawed. The costs and risks are too high - its like investing your savings entirely in the most risky biotech and penny stocks. Diversification is the only answer.
And China will no doubt introduce a new insulin called Porkalog M, which is pork insulin with melamine. It is a long-acting insulin.
And China will no doubt introduce a new insulin called Porkalog M, which is pork insulin with melamine. It is a long-acting insulin.
Yes....it will also be available in a sweet and sour version. Look for it on the menu beside Beef Hung Far Lo and Cream of Sum Yung Guy.......
